Balaxi Pharmaceuticals Limited

July 10, 2023

To, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Subject: Reconciliation of Share Capital Audit Report

Dear Sir/Madam,

Please find enclosed the Reconciliation of Share Capital Audit Report for Equity Shares of the Company for the quarter ended June 30, 2023. The report has been signed by Mr. Yogindunath S of BVR & Associates Company Secretaries LLP.

This report is submitted in compliance with Regulation 76 of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

This is for your information and records.

Yours Faithfully,

For Balaxi Pharmaceuticals Limited

Udayan Shukla (Company Secretary & Compliance Officer) Membership No.: F11744

Encl: As above

Registered Office: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096 CIN: L25191TG1942PLC121598 Phone: +91 40 23555300 Email: info@balaxi.in Website: www.balaxipharma.in

\mathbb{BVR} & associates

Company Secretaries LLP

LLP Identification No: AAE-7079

"Swastika", First Floor Chitteth House, P C Road Vytilla P. O., Cochin - 682 019 Ph: 0484 4046696, +91 98957 62686

To,

Balaxi Pharmaceuticals Limited

Plot No.409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No.81, Jubilee Hills, Hyderabad (T.G.) - 500096

Dear Sir/ Madam,

We have examined the relevant books, registers, forms, documents and papers produced electronically before us by **Balaxi Pharmaceuticals Limited** ('the Company') and its Registrars and Transfer Agent (RTA), Aarthi Consultants Private Limited, in respect of Reconciliation of Share Capital Audit as per Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. To the best of our knowledge and according to the information and explanations given to us, we certify the following:

1	For Quarter Ended	June 30, 2023
2	ISIN	INE618N01014
3	Face Value	Rs. 10/- per equity share
4	Name of the Company	Balaxi Pharmaceuticals Limited
5	Registered Office Address	Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad - 500096
6	Correspondence Address	Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad - 500096
7	Telephone & Fax Nos.	040 23555300
8	Email address	secretarial@balaxi.in

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT



9	Names of the Stock Exchanges where	National Stock Exchange of India		
	the company's securities are listed:	Limited (NSE)		
		Number of shares	% of Total	
		Number of shares	Issued Cap.	
10	Issued Capital	1,02,30,200	100%	
11	Listed Capital (Exchange wise) (as per company records) National Stock Exchange of India Limited (NSE)	1,02,30,200	100%	
12	Held in dematerialised form in CDSL	77,99,244	76.24%	
13	Held in dematerialised form in NSDL	23,89,596	23.36%	
14	Physical	41,360	0.40%	
15	Total No. of shares (12+13+14)	1,02,30,200	100.00%	
16	Reasons for difference if any, between (10 & 11), (10 & 15), (11 & 15)	Not Applicable		

17. Certifying the details of changes in share capital during the quarter under consideration as per Table below:

Particulars***	No. of	Applied	Listed on	Whether	Whether	In-prin.
	shares	/ Not	Stock	intimated	intimated	appr.
		Applied/	Exchanges	to CDSL	to NSDL	pending
		for listing				for SE
Allotment of	48,950	Already	Yes,	Yes	Yes	NA
Equity		Listed	Listed on			
Shares			NSE			
pursuant to						
conversion						
of warrants						
on May 09,						
2023						

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to specify).



18	Register of Members is updated (Yes/No)	Yes
19	Reference of previous quarter with regards to excess dematerialized shares, if any.	NIL
20	Has the company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason why?	Not Applicable

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 Days	NIL	NIL	NA
Pending for more than 21 days	NIL	NIL	NA

22	Name, Telephone & Fax No. of the Compliance	Udayan Shukla
	Officer of the Company.	Telephone No.: 040 2355
		5300
		Email: secretarial@balaxi.in
23	Name, Address, Tel. & Fax No., Regn. no. of the	CS. Yogindunath S
	Practicing Company Secretary certifying the	BVR & Associates
	report	Company Secretaries LLP,
		Swastika, First Floor,
		Chitteth Building, P C
		Road, Vytilla P.O, Cochin-
		682019
		Tel: 0484-4046696
		Membership No.: 7865
		Certificate of Practice No.:
		9137



		Peer Review No.: P2010KE020500
24	Appointment of common agency for share registry work (if yes, name and address)	Aarthi Consultants Private Limited 1-2-285, Domalguda, Hyderabad-500029 Ph: 040-27638111, 27634445 Fax: 040-27632184
25	Any other detail that the Company Secretary may like to provide. (e.g. BIFR company, delisting from SE,	Nil

YOGINDUNATH. S. Designated Partner BVR & Associates Company Secretaries LLF "Swastika", Chitteth Building PC Read, Pennurunni (E) Vyttilu P.O., Cochin - 682 019 C P No: \$137, FCS 7865 LLP IN AAE - 7079 -lögindunath S

BVR & Associates Company Secretaries LLP, Practicing Company Secretaries M NO:7865 CP:9137 UDIN: F007865E000574191

Date: 10/07/2023 Place: Cochin

